Extended studies of the striatal uptake of99mTc-NC100697 in healthy volunteers

Journal of Nuclear Medicine

Volumn 48, Issue 1, 2007, Pages 27-34

  Koch, Walter ^a   Pogarell, Oliver ^a   Pöpperl, Gabriele ^a   Hornung, Julia ^a   Hamann, Christine ^a   Gildehaus, Franz Josef ^a   Seelos, Klaus ^a   Lewis, Dewi ^b   Favit, Antonella ^b   Tatsch, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b GE HEALTHCARE   (United Kingdom)

Author keywords

Automated data processing; Dopamine transporter; Quantitative evaluation

Indexed keywords

2BETA [N,N9 BIS(2 MERCAPTOETHYL)ETHYLENEDIAMINOMETHYL] 3BETA (4 CHLOROPHENYL)TROPANE TC 99M; DOPAMINE TRANSPORTER; NC 100697; RADIOISOTOPE; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT; TECHNETIUM; TECHNETIUM 99M NC100697; TECHNETIUM COMPLEX;

ADULT; AGE; AGED; ARTICLE; CAUDATE NUCLEUS; CORPUS STRIATUM; DRUG FORMULATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; PREMENOPAUSE; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN BINDING; PUTAMEN; QUANTITATIVE ANALYSIS; RELIABILITY; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AUTOMATION; BRAIN; CLINICAL TRIAL; COHORT ANALYSIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; AUTOMATION; BRAIN; COHORT STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SEX FACTORS; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 33847284093     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266-272.
2. 123I]-FP-CIT study group. Mov Disord. 2000;15:503-510.
3. 2 transporter ligands. Eur J Nucl Med Mol Imaging. 2002;29:BP30-BP35.
4. Kung HF. Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent. Nucl Med Biol. 2001;28:505-508.
5. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med. 1996;23:1527-1530.
6. 99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372-380.
7. Choi SR, Kung MP, Plossl K, Meegalla S, Kung HF. An improved kit formulation of a dopamine transporter imaging agent: [Tc-99m]TRODAT-1. Nucl Med Biol. 1999;26:461-466.
8. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med. 2005;46:1109-1118.
9. Radau PE, Slomka PJ, Julin P, Svensson L, Wahlund LO. Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. Med Phys. 2001;28:1660-1668.
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
11. 93mTc]TRODAT-1: a new dopamine transporter imaging agent [abstract]. Proceedings of the XIIth International Symposium on Radiopharmaceutical Chemistry. Uppsala, Sweden: June 15-19, 1997:263-265.
12. Kao PF, Tzen KY, Yen TC, et al. The optimal imaging time for [99Tcm]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease. Nucl Med Commun. 2001;22:151-154.
13. 99mTc]TRODAT-1 binding to dopamine transporters in nonhuman primates using single-photon emission tomography. Eur J Nucl Med. 1999;26:518-526.
14. 99mTc] TRODAT-1 and single-photon emission tomography. Eur J Nucl Med. 2000;27:1714-1718.
15. 18F] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24-42.
16. 11C]raclopride binding to D2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 1989;9:696-708.
17. 123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14:982-994.
18. 99mTc- TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med. 2004;45:207-213.
19. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in health human subjects. Ann Neurol. 1994;36:237-239.
20. De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol. 1990;27:157-161.
21. Mozley PD, Acton PD, Barraclough ED, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med. 1999;40:1812-1817.
22. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. J Nucl Med. 2004;45:1694-1697.
23. Mozley PD, Kim HJ, Gur RC, et al. Iodine-123-IPT SPECT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values. J Nucl Med. 1996;37:1965-1970.
24. 11C]-raclopride. Ann N Y Acad Sci. 1993;695:81-85.
25. 11C-raclopride. Arch Neurol. 1993;50:474-480.
26. Wong DF, Young D, Wilson PD, Meltzer CC, Gjedde A. Quantification of neuroreceptors in the living human brain. III. D2-like dopamine receptors: theory, validation, and changes during normal aging. J Cereb Blood Flow Metab. 1997;17:316-330.
27. Ichise M, Ballinger JR, Tanaka F, et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med. 1998;39:1511-1518.
28. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol. 1990;28:799-804.
29. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993;34:423-431.
30. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993;90:11965-11969.
31. 123I]IPT and single-photon emission tomography. Eur J Nucl Med. 1997;24:415-421.
32. Tissingh G, Booij J, Bergmans P, et al. Iodine-123-N-omega-fluoropropyl- 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med. 1998;39:1143-1148.
33. 123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001;41:275-284.
34. 123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27:867-869.
35. Morissette M, Levesque D, Di Paolo T. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study. Mol Pharmacol. 1992;42:480-488.
36. Morissette M, Biron D, Di Paolo T. Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res Bull. 1990;25:419-422.
37. Pohjalainen T, Rinne JO, Nagren K, Syvalahti E, Hietala J. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry. 1998;155:768-773.
38. 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med. 2004;45:393-401.
39. 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging. 2004;31:1119-1127.